Eli Lilly
-
Eli Lilly expands immunology footprint with US$2.88B acquisition of Merida Biosciences
The acquisition will give Lilly access to Merida’s technology for developing biologics that selectively eliminate disease-causing autoantibodies.
-
Eli Lilly signs US$370M OmniAb deal for ion channel drug discovery
OmniAb was spun out of Ligand Pharmaceuticals in 2022 and has since built a broad network of pharmaceutical partnerships.
-
Eli Lilly wins UK MHRA approval for Foundayo weight-loss pill
The approval from the Medicines and Healthcare products Regulatory Agency (MHRA) marks another milestone in the rapidly growing market for oral weight-loss medicines.
-
Eli Lilly discontinues Gaucher type 1 gene therapy trial from Prevail buyout
Lilly disclosed the decision as part of its second-quarter results, removing a phase 1/2 study of LY3884961 in Gaucher disease type 1 (GD1) from its pipeline.
-
Eli Lilly partners with Resilience to invest US$750M in expanding KwikPen manufacturing in Ohio
The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.
-
Eli Lilly to acquire AtaiBeckley in US$2.8B deal to advance psychedelic treatments for depression
Under the terms of the agreement, Lilly will pay US$6.75 per share in cash, representing a 40% premium over AtaiBeckley’s 30-day volume-weighted average share price.
-
Eli Lilly outsources Verzenios’ commercial operations to China’s Innovative Biologics
Verzenios is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Lilly for the treatment of several forms of breast cancer.
-
Eli Lilly collaborates with Abu Dhabi’s DoH on precision medicine initiative at BIO 2026
The agreement brings together Lilly’s expertise in developing innovative medicines with Abu Dhabi’s advanced healthcare infrastructure, population-scale health data, and genomics capabilities.
-
Eli Lilly signs US$1B Alzheimer’s deal with AlzeCure Pharma for ACD680
The partnership grants Lilly global rights to AlzeCure’s preclinical small-molecule candidate, ACD680, which targets the biology of Alzheimer’s disease.
-
Eli Lilly signs US$1.26B deal with Hanmi for long-acting GLP-2 intestinal therapy
Under the agreement, Lilly will obtain exclusive worldwide rights, excluding South Korea, to develop, manufacture, and commercialise sonefpeglutide, a long-acting GLP-2 analogue.